USFDA issues three observations after Indore plant pre-approval inspection

Regulatory & Legal View source PDF Explain this filing

GUFICBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹388.00

prior close

₹391.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+4.6% vs market

Pharmaceuticals peers, median of 174sector+1.2%+3.8% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 3.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.1

10m

+3.0

15m

+3.7

30m

+3.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0+0.4+4.6+1.2+3.8

Next day

+7.7+2.1+5.6+3.1+4.6

+8.6pendingpending+4.7+3.9

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The USFDA inspected Gufic Biosciences' manufacturing facility in Indore from October 15 to October 23, 2026. The company received three observations and plans to address them with the regulator within the prescribed time. No financial, operational or product impact was stated.

Likely market impact

The observations could affect the facility's USFDA approval timing, but the filing does not state any immediate business impact.